Toxicity assays in eukaryotic cell cultures

Summary of the technology offered

  • A group of researchers from the Laboratory of Molecular and Cellular Biology of Lipids has experience in TLC techniques for the analysis and identification of phospholipids in samples of different origins.
  • The same research group has experience in identifying and evaluating different toxic effects caused by polymeric or elastomeric containers (plastic or rubber caps) materials for pharmaceutical use.
  • Researchers also have experience and have offered to carry out tests for cytotoxicity in cell cultures. The method is sensitive and reproducible to evaluate acute toxicity of synthetic and natural drugs in cells of human origin.
  • The laboratory has a bank of characterized eukaryotes lines available for commercial use.

Brief description of the technology offered

For toxicity testing, 96-well plates are used in which cells are treated with different concentrations of the study drug and the respective controls, then they are incubated and finally the survival of the cells is analyzed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT assay).

For toxicity testing of plastics, confluent cultures of L929 cell line and extracts from the material to be tested are used. Toxicity is assessed by determining growth inhibition halos.

Qualitative and quantitative determinations of phospholipids are carried out using silica plates and TLC analyses.

Application domain

  • Health.
  • Pharmaceutical, food and plastic products industry.


  • Plastic industries that need to control the toxicity of packaging (serum, disposable, medicine, food, etc.).
  • The toxicity assay detects toxic effects on human cells, by using cell lines proliferation in in vitro culture. Pure compounds, mixtures of compounds or complex samples of natural origin can be tested. Furthermore, this assay allows the analysis of the potential compound as a candidate for the development of antitumor drugs.
  • The phospholipids analysis provides the possibility to analyze these compounds in companies interested in developing diagnostic kits using these molecules as antigens in determining autoimmune and infectious diseases.

State of development

  • Tested in the laboratory.
  • Available for demonstration

State of intellectual property

Secret know-how.

Details of potential operating or partnership agreements

  • Technical cooperation.
  • Joint Venture.
  • Technical support..


Dr. Claudia Banchio.